EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches

Michele Migliari, Luca Fazzini, Nicola Campana, Martino Deidda, Mariele Dessì, Christian Cadeddu Dessalvi

Frontiers in Cardiovascular Medicine · 23.10.2025 · 12

DOI: 10.3389/fcvm.2025.1668308 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 23.10.2025. Verfasst von Michele Migliari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiotoxicity is a major concern in cancer survivors, potentially compromising treatment efficacy, quality of life and long-term survival. With increasing survival rates, the need for effective cardioprotective strategies has become paramount.

Objective

This narrative review evaluates current pharmacological, non-pharmacological, and emerging strategies for preventing cancer therapy-related cardiac dysfunction (CTR-CD), emphasizing recent advances, their clinical applicability and research gaps.

Methods

We conducted a narrative review based on a non-systematic search of PubMed/MEDLINE, Scopus, and Web of Science up to June 2025, focusing on clinical trials, meta-analyses, guideline recommendations, and key observational studies relevant to CTR-CD prevention.

Results

Among pharmacological approaches, renin-angiotensin-aldosterone system inhibitors (RAASi) and beta-blockers modestly preserve left ventricular ejection fraction (LVEF), though benefits on hard outcomes remain unproven. Dexrazoxane is the only FDA-approved agent and shows robust protection in anthracycline-treated patients. Statins and metformin demonstrate promising but still investigational cardioprotective effects, while sodium-glucose cotransporter-2 inhibitors (SGLT2i) show encouraging pilot data. Non-pharmacological strategies—including structured exercise, mediterranean diet, nutritional support and aggressive control of risk factors—are guideline-endorsed, although most evidence relies on surrogate endpoints. Emerging tools such as telemedicine, artificial intelligence and omics sciences offer innovative opportunities for personalized prevention but require multicenter validation.

Conclusion

An integrated, multidisciplinary approach combining both pharmacological and non-pharmacological strategies is essential to effectively prevent cardiotoxicity in cancer patients. Current evidence supports dexrazoxane, risk factor control and selective use of RAASi or beta-blocker in high-risk patients. Exercise and nutrition provide functional and quality of life benefits, while several novel strategies remain exploratory. Future large-scale, multicenter, randomized trial are needed to harmonize international guidelines and define the most effective, sustainable prevention models across diverse patient populations.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligentecancer therapy-related cardiac dysfunctioncardio-oncologycardiotoxicitynon-pharmacological strategiespharmacological strategiesprevention

Autor:innen und Institutionen

  • Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Zitieren

APA

Migliari, M., Fazzini, L., Campana, N., Deidda, M., Dessì, M., & Cadeddu Dessalvi, C. (2025). Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1668308

Vancouver

Migliari M, Fazzini L, Campana N, Deidda M, Dessì M, Cadeddu Dessalvi C. Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1668308

BibTeX
@article{Migliari2025,
  author = {Migliari, Michele and Fazzini, Luca and Campana, Nicola and Deidda, Martino and Dessì, Mariele and Cadeddu Dessalvi, Christian},
  title = {Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2025},
  volume = {12},
  doi = {10.3389/fcvm.2025.1668308}
}
Kostenlos starten →